Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial

BACKGROUND: Long-acting injectable cabotegravir (CAB LA) is a novel integrase inhibitor in advanced clinical development for HIV treatment and HIV prevention. We investigated the terminal pharmacokinetics and safety of CAB LA after final injection as part of a Phase 2 study. METHODS: We performed a...

詳細記述

保存先:
書誌詳細
出版年:Lancet HIV
主要な著者: Landovitz, Raphael J., Li, Sue, Eron, Joseph J., Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y., Magnus, Manya, Hosseinipour, Mina C., Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A., Eshleman, Susan H., Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R., Margolis, David, Cohen, Myron S., McCauley, Marybeth, Hendrix, Craig W.
フォーマット: Artigo
言語:Inglês
出版事項: 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7859863/
https://ncbi.nlm.nih.gov/pubmed/32497491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3018(20)30106-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料